Cargando…
Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library
Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat for effective treatment of several difficult-to-treat infections in humans. To identify potential new treatment options for MRSA infections, we screened a clinical compound library consisting of 1524 compounds using a grow...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618001/ https://www.ncbi.nlm.nih.gov/pubmed/28930155 http://dx.doi.org/10.3390/pathogens6030044 |
_version_ | 1783267088979197952 |
---|---|
author | Niu, Hongxia Yee, Rebecca Cui, Peng Tian, Lili Zhang, Shuo Shi, Wanliang Sullivan, David Zhu, Bingdong Zhang, Wenhong Zhang, Ying |
author_facet | Niu, Hongxia Yee, Rebecca Cui, Peng Tian, Lili Zhang, Shuo Shi, Wanliang Sullivan, David Zhu, Bingdong Zhang, Wenhong Zhang, Ying |
author_sort | Niu, Hongxia |
collection | PubMed |
description | Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat for effective treatment of several difficult-to-treat infections in humans. To identify potential new treatment options for MRSA infections, we screened a clinical compound library consisting of 1524 compounds using a growth inhibition assay in 96-well plates. We identified 34 agents which are either bacteriostatic or bactericidal against log-phase clinical MRSA strain USA300. Among them, 9 candidates (thonzonium, cetylpyridinium, trilocarban, benzododecinium, bithionol, brilliant green, chlorquinaldol, methylbenzethonium and green violet) are known antiseptics, 11 candidates are known antibiotics currently recommended for the treatment of MRSA. We identified 9 new drug candidates, 5 of which (thiostrepton, carbomycin, spiramycin, clofazimine and chloroxine) are antibiotics used for treating other infections than S. aureus infections; 4 of which (quinaldine blue, closantel, dithiazanine iodide and pyrvinium pamoate) are drugs used for treating parasitic diseases or cancer. We ranked these new drug candidates according to their MICs against the MRSA strain USA300. Our findings may have implications for more effective treatment of MRSA infections. |
format | Online Article Text |
id | pubmed-5618001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56180012017-09-30 Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library Niu, Hongxia Yee, Rebecca Cui, Peng Tian, Lili Zhang, Shuo Shi, Wanliang Sullivan, David Zhu, Bingdong Zhang, Wenhong Zhang, Ying Pathogens Article Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat for effective treatment of several difficult-to-treat infections in humans. To identify potential new treatment options for MRSA infections, we screened a clinical compound library consisting of 1524 compounds using a growth inhibition assay in 96-well plates. We identified 34 agents which are either bacteriostatic or bactericidal against log-phase clinical MRSA strain USA300. Among them, 9 candidates (thonzonium, cetylpyridinium, trilocarban, benzododecinium, bithionol, brilliant green, chlorquinaldol, methylbenzethonium and green violet) are known antiseptics, 11 candidates are known antibiotics currently recommended for the treatment of MRSA. We identified 9 new drug candidates, 5 of which (thiostrepton, carbomycin, spiramycin, clofazimine and chloroxine) are antibiotics used for treating other infections than S. aureus infections; 4 of which (quinaldine blue, closantel, dithiazanine iodide and pyrvinium pamoate) are drugs used for treating parasitic diseases or cancer. We ranked these new drug candidates according to their MICs against the MRSA strain USA300. Our findings may have implications for more effective treatment of MRSA infections. MDPI 2017-09-20 /pmc/articles/PMC5618001/ /pubmed/28930155 http://dx.doi.org/10.3390/pathogens6030044 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Niu, Hongxia Yee, Rebecca Cui, Peng Tian, Lili Zhang, Shuo Shi, Wanliang Sullivan, David Zhu, Bingdong Zhang, Wenhong Zhang, Ying Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library |
title | Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library |
title_full | Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library |
title_fullStr | Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library |
title_full_unstemmed | Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library |
title_short | Identification of Agents Active against Methicillin-Resistant Staphylococcus aureus USA300 from a Clinical Compound Library |
title_sort | identification of agents active against methicillin-resistant staphylococcus aureus usa300 from a clinical compound library |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618001/ https://www.ncbi.nlm.nih.gov/pubmed/28930155 http://dx.doi.org/10.3390/pathogens6030044 |
work_keys_str_mv | AT niuhongxia identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary AT yeerebecca identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary AT cuipeng identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary AT tianlili identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary AT zhangshuo identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary AT shiwanliang identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary AT sullivandavid identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary AT zhubingdong identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary AT zhangwenhong identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary AT zhangying identificationofagentsactiveagainstmethicillinresistantstaphylococcusaureususa300fromaclinicalcompoundlibrary |